{"schema_version":"secwatch.filing_event.v1","accession":"0000879407-25-000004","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.552303+00:00","generated_at":"2026-05-17T09:07:24.755224+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arrowhead licenses ARO-SNCA to Novartis for $200M upfront, up to $2B milestones","bullets":["Arrowhead receives $200M upfront; eligible for up to $2B in development, regulatory, sales milestones.","Novartis gets exclusive worldwide license to preclinical ARO-SNCA (siRNA for synucleinopathies like Parkinson's).","Arrowhead will complete preclinical work; Novartis handles clinical development, manufacturing, commercialization.","Arrowhead eligible for tiered royalties up to low double digits on net product sales.","Transaction expected to close H2 2025, subject to HSR antitrust clearance and customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0000879407-25-000004","json":"https://secwatch.observer/filing/0000879407-25-000004.json","markdown":"https://secwatch.observer/filing/0000879407-25-000004.md","text":"https://secwatch.observer/filing/0000879407-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000087940725000004/0000879407-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000087940725000004/arwr-20250902.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:07:24.755224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}